Fiaz Shaukat, Ali Azfar, Adnan Siddique, Khalil Muhammad Arshad Irshad, Rasheed Yasir, Abu Bakar Muhammad, Ahmad Cheema Zubair, Mir Khurram
Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, PAK.
Urology, Instutute of Kidney Diseases Hayat Abad Medical Complex, Peshawar, PAK.
Cureus. 2020 Aug 26;12(8):e10057. doi: 10.7759/cureus.10057.
Introduction Radical cystectomy (RC) is the current standard of care for treating muscle-invasive bladder cancer (MIBC), however bladder preservation by offering radical radiotherapy (RT) is gaining interest for improving the quality of life while maintaining a reasonable oncological outcome. In this study, we have compared outcomes of the two treatment options. Materials and methods This is a 10-year retrospective cohort study that included all patients who were treated for histologically proven muscle-invasive bladder cancer in the department of uro-oncology at Shaukat Khanum Memorial Cancer Hospital and Research Centre from January 2005 to January 2015. Data was analysed using Statistical Product and Service Solutions (SPSS), version 21 (IBM Corp., Armonk, NY). The primary end point of our study was to calculate the three- and five-year disease-free survival (DFS) and overall survival (OS). Results A total of 230 patients were included in the study with male gender predominating (88%). The mean and standard deviation for age was 58.32+11.128. Radical cystectomy was performed in 119 patients while 111 received RT. Clinically, 34% had stage 2 disease, while 66 % had stage 3 cancer. The median follow-up duration was 41 months (range: 2-155). During follow-up 57.4% of patients showed no recurrence. Local recurrence was found in 9.6% patients and distant metastasis in 32.2%. The three-year DFS of RC was 63% and that of RT was 57% while the five-year DFS for RC and RT were 60% and 49%, respectively (p=0.196). The three-year OS of RC was 64% and that for RT was 58%. On further analysis the five-year OS of RC was 53% and that for RT was 50% (p=0.98). Upon stage-based comparisons, we found no statistically significant difference between the three- and five-year DFS and OS of stage 2 and stage 3 when treated with either modality. Conclusion Most studies favor RC and consider it as the gold standard treatment for muscle-invasive bladder tumor treatment. The current study reveals that bladder preservation approach by chemo radiotherapy is a viable treatment option, having comparable oncological outcomes with patients receiving radical cystectomy, and can be offered to patients having muscle-invasive urothelial bladder cancer.
引言
根治性膀胱切除术(RC)是目前治疗肌层浸润性膀胱癌(MIBC)的标准治疗方法,然而,通过提供根治性放疗(RT)来保留膀胱,在改善生活质量同时维持合理的肿瘤学结局方面正受到越来越多的关注。在本研究中,我们比较了这两种治疗方案的结局。
材料与方法
这是一项为期10年的回顾性队列研究,纳入了2005年1月至2015年1月在沙卡特汗姆纪念癌症医院和研究中心泌尿肿瘤科接受组织学证实的肌层浸润性膀胱癌治疗的所有患者。使用统计产品与服务解决方案(SPSS)21版(IBM公司,纽约州阿蒙克)进行数据分析。我们研究的主要终点是计算三年和五年无病生存率(DFS)及总生存率(OS)。
结果
共有230例患者纳入研究,男性占主导(88%)。年龄的均值和标准差为58.32±11.128。119例患者接受了根治性膀胱切除术,111例接受了放疗。临床上,34%为2期疾病,66%为3期癌症。中位随访时间为41个月(范围:2 - 155个月)。随访期间,57.4%的患者未出现复发。9.6%的患者出现局部复发,32.2%出现远处转移。根治性膀胱切除术的三年DFS为63%,放疗为57%,而根治性膀胱切除术和放疗的五年DFS分别为60%和49%(p = 0.196)。根治性膀胱切除术的三年OS为64%,放疗为58%。进一步分析显示,根治性膀胱切除术的五年OS为53%,放疗为50%(p = 0.98)。基于分期的比较中,我们发现2期和3期患者接受任何一种治疗方式时,三年和五年DFS及OS之间均无统计学显著差异。
结论
大多数研究支持根治性膀胱切除术,并将其视为肌层浸润性膀胱肿瘤治疗的金标准。本研究表明,化疗放疗保留膀胱的方法是一种可行的治疗选择,其肿瘤学结局与接受根治性膀胱切除术的患者相当,可提供给患有肌层浸润性尿路上皮膀胱癌的患者。